Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

ABSTRACT In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guillaume Beaudoin-Bussières, Annemarie Laumaea, Sai Priya Anand, Jérémie Prévost, Romain Gasser, Guillaume Goyette, Halima Medjahed, Josée Perreault, Tony Tremblay, Antoine Lewin, Laurie Gokool, Chantal Morrisseau, Philippe Bégin, Cécile Tremblay, Valérie Martel-Laferrière, Daniel E. Kaufmann, Jonathan Richard, Renée Bazin, Andrés Finzi
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	coronavirus COVID-19 SARS-CoV-2 Spike glycoproteins RBD ELISA Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/ffd03ff044094e43ad2ac82e96e702dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ffd03ff044094e43ad2ac82e96e702dd
record_format	dspace
spelling	oai:doaj.org-article:ffd03ff044094e43ad2ac82e96e702dd2021-11-15T16:19:10ZDecline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals10.1128/mBio.02590-202150-7511https://doaj.org/article/ffd03ff044094e43ad2ac82e96e702dd2020-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.02590-20https://doaj.org/toc/2150-7511ABSTRACT In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms. IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.Guillaume Beaudoin-BussièresAnnemarie LaumaeaSai Priya AnandJérémie PrévostRomain GasserGuillaume GoyetteHalima MedjahedJosée PerreaultTony TremblayAntoine LewinLaurie GokoolChantal MorrisseauPhilippe BéginCécile TremblayValérie Martel-LaferrièreDaniel E. KaufmannJonathan RichardRenée BazinAndrés FinziAmerican Society for MicrobiologyarticlecoronavirusCOVID-19SARS-CoV-2Spike glycoproteinsRBDELISAMicrobiologyQR1-502ENmBio, Vol 11, Iss 5 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	coronavirus COVID-19 SARS-CoV-2 Spike glycoproteins RBD ELISA Microbiology QR1-502
spellingShingle	coronavirus COVID-19 SARS-CoV-2 Spike glycoproteins RBD ELISA Microbiology QR1-502 Guillaume Beaudoin-Bussières Annemarie Laumaea Sai Priya Anand Jérémie Prévost Romain Gasser Guillaume Goyette Halima Medjahed Josée Perreault Tony Tremblay Antoine Lewin Laurie Gokool Chantal Morrisseau Philippe Bégin Cécile Tremblay Valérie Martel-Laferrière Daniel E. Kaufmann Jonathan Richard Renée Bazin Andrés Finzi Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
description	ABSTRACT In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms. IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.
format	article
author	Guillaume Beaudoin-Bussières Annemarie Laumaea Sai Priya Anand Jérémie Prévost Romain Gasser Guillaume Goyette Halima Medjahed Josée Perreault Tony Tremblay Antoine Lewin Laurie Gokool Chantal Morrisseau Philippe Bégin Cécile Tremblay Valérie Martel-Laferrière Daniel E. Kaufmann Jonathan Richard Renée Bazin Andrés Finzi
author_facet	Guillaume Beaudoin-Bussières Annemarie Laumaea Sai Priya Anand Jérémie Prévost Romain Gasser Guillaume Goyette Halima Medjahed Josée Perreault Tony Tremblay Antoine Lewin Laurie Gokool Chantal Morrisseau Philippe Bégin Cécile Tremblay Valérie Martel-Laferrière Daniel E. Kaufmann Jonathan Richard Renée Bazin Andrés Finzi
author_sort	Guillaume Beaudoin-Bussières
title	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
title_short	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
title_full	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
title_fullStr	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
title_full_unstemmed	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
title_sort	decline of humoral responses against sars-cov-2 spike in convalescent individuals
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/ffd03ff044094e43ad2ac82e96e702dd
work_keys_str_mv	AT guillaumebeaudoinbussieres declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT annemarielaumaea declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT saipriyaanand declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT jeremieprevost declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT romaingasser declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT guillaumegoyette declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT halimamedjahed declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT joseeperreault declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT tonytremblay declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT antoinelewin declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT lauriegokool declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT chantalmorrisseau declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT philippebegin declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT ceciletremblay declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT valeriemartellaferriere declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT danielekaufmann declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT jonathanrichard declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT reneebazin declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals AT andresfinzi declineofhumoralresponsesagainstsarscov2spikeinconvalescentindividuals
_version_	1718426946069594112

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Ejemplares similares